Kidney Week

Abstract: SA-PO1119

From Admission to the Present: Clinical Effect and Quality of Life in Patients on Hemodialysis in a Secondary-Level Hospital in Mexico City

Session Information

• Kidney Replacement Therapy and Care Delivery Innovations
  October 24, 2026 | Location: Exhibit Hall A, Convention Center
  Abstract Time: 10:00 AM - 12:00 PM

Category: Dialysis

• 801 Dialysis: Hemodialysis and Frequent Dialysis

Authors

• Mora Loján, José Luis, Dr. Manuel Gea González General Hospital, Ciudad de México, Mexico

José Luis Mora Loján, MD

• Zorrilla Alfaro, Sideré Monserrath, Dr. Manuel Gea González General Hospital, Ciudad de México, Mexico

Sideré Monserrath Zorrilla Alfaro, MD

• Reyes Torres, Bruno Eduardo, Dr. Manuel Gea González General Hospital, Ciudad de México, Mexico

Bruno Eduardo Reyes Torres, MD

• Juarez, Joana Balderas, Dr. Manuel Gea González General Hospital, Ciudad de México, Mexico

Joana Balderas Juarez, MD

• Salinas-Ramirez, Mauricio Adrian, Dr. Manuel Gea González General Hospital, Ciudad de México, Mexico

Mauricio Adrian Salinas-Ramirez, MD

• Hernández Castillo, José Luis, Dr. Manuel Gea González General Hospital, Ciudad de México, Mexico

José Luis Hernández Castillo, MD

Background

Hemodialysis impacts patients' clinical parameters and quality of life. Determining its scope requires integrating laboratory tests with quality of life measures that capture symptoms, functioning, and well-being, allowing for a comprehensive assessment. Local evidence documenting this transition remains limited; therefore, the objective is to estimate the clinical and quality-of-life impact between two intraindividual measurements (prior to treatment initiation in the unit and current status) in hemodialysis patients at a secondary-level hospital in Mexico City.

Methods

This was an observational, longitudinal study with repeated measurements (pre-post) in hemodialysis patients, conducted between April and August 2025 at a hemodialysis unit of a secondary-level hospital in Mexico City. Data were collected on laboratory tests, medications, and hemodialysis parameters. Quality of life was assessed using the KDQOL-36 (three specific domains and composite physical and mental domains; 0–100 scale, with higher scores indicating better health).

Results

Nineteen individuals were analyzed (51 ± 13 years; 78.9% with a catheter). The symptoms/problems domain improved from 81.25 to 89.58 (p = 0.011). Favorable trends were observed in the burden of kidney disease (31.25 → 43.75; p = 0.106) and in the mental composite (45.64 → 54.22; p = 0.064); no changes were observed in the physical composite (p = 0.446) or in the effects of kidney disease (p = 0.223). In laboratory tests, calcium increased from 8.30 to 8.80 mg/dL (p = 0.006); phosphorus (p = 0.070), urea (p = 0.085), and blood urea nitrogen (p = 0.170) decreased, though not significantly; hemoglobin showed an upward trend (p = 0.157).

Conclusion

When comparing the baseline assessment with the current measurement, a significant improvement in symptoms and a favorable adjustment of calcium were observed, with benefit in perceived burden and mental health, without changes in the physical component or in the effects of the disease; these findings support systematically integrating quality of life and clinical goals in hemodialysis.